CLLS

Cellectis SA

Add to Watchlist

Advanced Chart

2.850

+0.08(2.888%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.890

Open

2.770

VWAP

2.85

Vol

17.91K

Mkt Cap

205.47M

Low

2.770

Amount

50.97K

EV/EBITDA(TTM)

Total Shares

71.96M

119.37M

EV/OCF(TTM)

P/S(TTM)

4.45

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2029Q4

FY2029Q3

FY2029Q2

9.15M

-23.76%

8.12M

-75.52%

7.86M

-56.39%

Estimates Revision

The market is revising Upward the revenue expectations for Cellectis S.A. (CLLS) for FY2025, with the revenue forecasts being adjusted by 1.24% over the past three months. During the same period, the stock price has changed by 93.88%.

Revenue Estimates for FY2025

Revise Upward

+1.24%

In Past 3 Month

Stock Price

Go Up

+93.88%

In Past 3 Month

4 Analyst Rating

11.23% Upside

Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 3.17 USD with a low forecast of 2.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

11.23% Upside

Current: 2.850

Low

2.50

Averages

3.17

High

4.00

11.23% Upside

Current: 2.850

Low

2.50

Averages

3.17

High

4.00

Barclays

Overweight

downgrade

$5 -> $4

2025-05-13

Reason

Barclays

Price Target

$5 -> $4

2025-05-13

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Cellectis to $4 from $5 and keeps an Overweight rating on the shares. The company's Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.

Barclays

Gena Wang

Buy

Maintains

$7 → $5

2024-11-05

Reason

Barclays

Gena Wang

Price Target

$7 → $5

2024-11-05

Maintains

Buy

Reason

Barclays lowered the firm's price target on Cellectis to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cellectis SA (CLLS.O) is -2.48, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Cellectis SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.08

Current PE

-2.48

Overvalued PE

0.30

Undervalued PE

-4.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.89

Current EV/EBITDA

-2.49

Overvalued EV/EBITDA

-0.75

Undervalued EV/EBITDA

-5.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.94

Current PS

3.48

Overvalued PS

9.80

Undervalued PS

2.09